J&J's Ethicon Calls For Game-Changing Holistic Approach To Obesity Care
At this year's 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Diseases, Johnson & Johnson subsidiary Ethicon launched a new initiative to significantly alter the way obesity is viewed and to change the patient care pathway for the better.
You may also be interested in...
Animas, a division of Johnson & Johnson, will stop making Animas Vibe and OneTouch Ping insulin pumps, close operations, and exit the insulin pump business, the company announced Oct. 5. J&J is offering patients currently using these devices the option to transfer to Medtronic device. Medtronic is already the leading supplier of insulin pumps worldwide.
With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.
At the LSX World Congress in London, leaders from Medtronic, Johnson & Johnson and Olympus discussed the evolving medtech mergers and acquisitions landscape, the big opportunity in robotic surgery and the impacts on innovation of the forthcoming EU Medical Device Regulation.